that’s the problem Peter Newman and David King (2023) in their answer JAMA Research letter published today. They used 1990-2021 data from the Tufts Medical Center CEA Registry. The results are summarized in the figure below.
First, we saw that the use of explicit cost-effectiveness thresholds increased over time, from just 45% of published studies to 91% of all studies. Second, the cost-effectiveness threshold has increased over time. Whereas 43.6% of studies reporting a CEA threshold used a threshold of $50,000/QALY in the 1990s and only 13.8% use it now; while 0% of studies used a threshold of $150,000/QALY in the Research does this.
The authors also point out:
- Higher thresholds were cited for cancer-related CEAs compared to non-cancer CEAs, which may indicate a view that higher thresholds are required for intervention in diseases associated with higher mortality and morbidity.
- Authors of industry funding analyzes tend to cite higher thresholds.
you can read the full text here.
